{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T16:42:29Z","timestamp":1785256949581,"version":"3.55.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018541","name":"Natural Science Foundation of Jiangsu Province for Distinguished Young Scholars","doi-asserted-by":"publisher","award":["BK20200005"],"award-info":[{"award-number":["BK20200005"]}],"id":[{"id":"10.13039\/501100018541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72174207"],"award-info":[{"award-number":["72174207"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hormone receptor-positive\/human epidermal growth factor receptor 2-negative (HR\u2009+\u2009\/HER2\u2009\u2212) advanced breast cancer is a prevalent subtype among postmenopausal women. Despite the growing number of randomized clinical trials (RCTs) exploring this topic, the efficacy and safety of first-line and second\/further-line treatments remain uncertain. Accordingly, our aim was to conduct a comprehensive evaluation of the efficacy and safety of these therapies through network meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>RCTs were identified by searching Pubmed, Embase, and major cancer conferences. The efficacy of interventions was assessed using the hazard ratios (HRs) of progression-free survival (PFS) and overall survival (OS), while safety was indicated by the incidence of any grade adverse events (AEs), grade 3\u20135 AEs, AEs leading to treatment discontinuation, and AEs leading to death. Both time-variant HRs fractional polynomial models and time-invariant HRs Cox-proportional hazards models were considered for handling time-to-event data. Safety indicators were analyzed using Bayesian network meta-analysis. Additionally, subgroup analyses were conducted based on patient characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 41 RCTs (first-line 17, second\/further-lines 27) were included in the analysis. For first-line treatment, the addition of Cyclin-dependent kinase 4 and 6 (CDK4\/6) inhibitors to endocrine therapy significantly improved therapeutic efficacy in terms of both PFS and OS, demonstrating the best performance across all mechanisms. Specifically, the combination of Abemaciclib and Letrozole demonstrated the most favorable performance in terms of PFS, while Ribociclib plus Fulvestrant yielded the best outcomes in OS. Incorporating the immune checkpoint inhibitor Avelumab into the regimen with CDK4\/6 inhibitors and selective estrogen receptor degraders significantly enhanced both PFS and OS in second-line or later treatments. Regarding safety, endocrine monotherapy performed well. Regarding safety, endocrine monotherapy performed well. There is mounting evidence suggesting that most CDK4\/6 inhibitors may demonstrate poorer performance with respect to hematologic AEs. However, additional evidence is required to further substantiate these findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>CDK4\/6 inhibitors, combined with endocrine therapy, are pivotal in first-line treatment due to their superior efficacy and manageable AEs. For second\/further-line treatment, adding immune checkpoint inhibitors to CDK4\/6 inhibitors plus endocrine therapy may produce promising results. However, to reduce the results\u2019 uncertainty, further trials comparing these novel treatments are warranted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>Registration number: PROSPERO (CRD42022377431).<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12916-023-03238-2","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T01:02:08Z","timestamp":1705021328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A network meta-analysis of efficacy and safety for first-line and second\/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer"],"prefix":"10.1186","volume":"22","author":[{"given":"Hanqiao","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingye","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Jia","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taihang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dachuang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"key":"3238_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3238_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022;66:15\u201323.","journal-title":"Breast"},{"key":"3238_CR3","unstructured":"SEER Cancer Stat Facts. https:\/\/seer.cancer.gov\/statfacts\/. Accessed 17 Dec 2023."},{"key":"3238_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3322\/caac.21777","volume":"73","author":"LA Huppert","year":"2023","unstructured":"Huppert LA, Gumusay O, Idossa D, Rugo HS. Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J Clin. 2023;73:480\u2013515.","journal-title":"CA Cancer J Clin"},{"key":"3238_CR5","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.21754","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022;72:524\u201341.","journal-title":"CA Cancer J Clin"},{"key":"3238_CR6","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41598-021-81538-4","volume":"11","author":"M Rossing","year":"2021","unstructured":"Rossing M, Pedersen CB, Tvedskov T, Vejborg I, Talman ML, Olsen LR, et al. Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status. Sci Rep. 2021;11:2259.","journal-title":"Sci Rep"},{"key":"3238_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.13017","volume":"6","author":"JA Mouabbi","year":"2023","unstructured":"Mouabbi JA, Singareeka RA, Bassett RJ, Hassan A, Tripathy D, Layman RM. Survival outcomes in patients with hormone receptor-positive metastatic breast cancer with low or no ERBB2 expression treated with targeted therapies plus endocrine therapy. JAMA Netw Open. 2023;6: e2313017.","journal-title":"JAMA Netw Open"},{"key":"3238_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10549-021-06383-5","volume":"190","author":"JA Mouabbi","year":"2021","unstructured":"Mouabbi JA, Osborne CK, Schiff R, Rimawi MF. Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer. Breast Cancer Res Treat. 2021;190:189\u2013201.","journal-title":"Breast Cancer Res Treat"},{"key":"3238_CR9","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3390\/cancers11111661","volume":"11","author":"V Rossi","year":"2019","unstructured":"Rossi V, Berchialla P, Giannarelli D, Nistico C, Ferretti G, Gasparro S, et al. Should all patients with HR-positive HER2-negative metastatic breast cancer receive CDK 4\/6 inhibitor as first-line based therapy? A network meta-analysis of data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT trials. Cancers (Basel). 2019;11:1661.","journal-title":"Cancers (Basel)"},{"key":"3238_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2020.100606","volume":"44","author":"Y Han","year":"2020","unstructured":"Han Y, Wang J, Wang Z, Xu B. Comparative efficacy and safety of CDK4\/6 and PI3K\/AKT\/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis. Curr Probl Cancer. 2020;44: 100606.","journal-title":"Curr Probl Cancer"},{"key":"3238_CR11","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1186\/s12885-023-11322-2","volume":"23","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wu J, Ji Z, Chen L, Zou J, Zheng J, et al. Comparative efficacy and safety of different combinations of three CDK4\/6 inhibitors with endocrine therapies in HR+\/HER-2 - metastatic or advanced breast cancer patients: a network meta-analysis. BMC Cancer. 2023;23:816.","journal-title":"BMC Cancer"},{"key":"3238_CR12","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1186\/s12885-023-11290-7","volume":"23","author":"D Ji","year":"2023","unstructured":"Ji D, Luo Y, Wang J, Chen S, Lan B, Ma F, et al. CDK4\/6 inhibitors, PI3K\/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis. BMC Cancer. 2023;23:805.","journal-title":"BMC Cancer"},{"key":"3238_CR13","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/S1470-2045(19)30420-6","volume":"20","author":"M Giuliano","year":"2019","unstructured":"Giuliano M, Schettini F, Rognoni C, Milani M, Jerusalem G, Bachelot T, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019;20:1360\u20139.","journal-title":"Lancet Oncol"},{"key":"3238_CR14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1177\/09622802211070253","volume":"31","author":"SC Freeman","year":"2022","unstructured":"Freeman SC, Cooper NJ, Sutton AJ, Crowther MJ, Carpenter JR, Hawkins N. Challenges of modelling approaches for network meta-analysis of time-to-event outcomes in the presence of non-proportional hazards to aid decision making: Application to a melanoma network. Stat Methods Med Res. 2022;31:839\u201361.","journal-title":"Stat Methods Med Res"},{"key":"3238_CR15","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/sim.9259","volume":"41","author":"PC Austin","year":"2022","unstructured":"Austin PC, Fang J, Lee DS. Using fractional polynomials and restricted cubic splines to model non-proportional hazards or time-varying covariate effects in the Cox regression model. Stat Med. 2022;41:612\u201324.","journal-title":"Stat Med"},{"key":"3238_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384.","journal-title":"Ann Intern Med"},{"key":"3238_CR17","unstructured":"Guidance for Industry on Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics; Availability. https:\/\/www.federalregister.gov\/documents\/2007\/05\/16\/E7-9345\/guidance-for-industry-on-clinical-trial-endpoints-for-the-approval-of-cancer-drugs-and-biologics. Accessed 16 Dec 2023."},{"key":"3238_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928.","journal-title":"BMJ"},{"key":"3238_CR19","unstructured":"PubChem. https:\/\/pubchem.ncbi.nlm.nih.gov\/. Accessed 16 Dec 2023."},{"key":"3238_CR20","unstructured":"Comprehensive Cancer Information. https:\/\/www.cancer.gov\/. Accessed 16 Dec 2023."},{"key":"3238_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"key":"3238_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"3238_CR23","unstructured":"CHTE2020 sources and synthesis of evidence. https:\/\/www.sheffield.ac.uk\/nice-dsu\/methods-development\/chte2020-sources-and-synthesis-evidence. Accessed 16 Dec 2023."},{"key":"3238_CR24","doi-asserted-by":"crossref","unstructured":"Patricia M. Grambsch TMT. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515\u201326.","DOI":"10.1093\/biomet\/81.3.515"},{"key":"3238_CR25","doi-asserted-by":"crossref","unstructured":"Ng\u2019Andu NH. An empirical comparison of statistical tests for assessing the proportional hazards assumption of Cox\u2019s model. Stat Med. 1997;16:611\u201326.","DOI":"10.1002\/(SICI)1097-0258(19970330)16:6<611::AID-SIM437>3.3.CO;2-K"},{"key":"3238_CR26","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","volume":"7","author":"SP Brooks","year":"1998","unstructured":"Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat. 1998;7:434\u201355.","journal-title":"J Comput Graph Stat"},{"key":"3238_CR27","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1080\/13696998.2022.2030599","volume":"25","author":"M Cooper","year":"2022","unstructured":"Cooper M, Smith S, Williams T, Aguiar-Ibanez R. How accurate are the longer-term projections of overall survival for cancer immunotherapy for standard versus more flexible parametric extrapolation methods? J Med Econ. 2022;25:260\u201373.","journal-title":"J Med Econ"},{"key":"3238_CR28","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jval.2020.03.010","volume":"23","author":"A Wiksten","year":"2020","unstructured":"Wiksten A, Hawkins N, Piepho HP, Gsteiger S. Nonproportional hazards in network meta-analysis: efficient strategies for model building and analysis. Value Health. 2020;23:918\u201327.","journal-title":"Value Health"},{"key":"3238_CR29","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12874-019-0829-2","volume":"19","author":"A Beliveau","year":"2019","unstructured":"Beliveau A, Boyne DJ, Slater J, Brenner D, Arora P. BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network Meta-analyses. BMC Med Res Methodol. 2019;19:196.","journal-title":"BMC Med Res Methodol"},{"key":"3238_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1167","volume":"7","author":"G van Valkenhoef","year":"2016","unstructured":"van Valkenhoef G, Dias S, Ades AE, Welton NJ. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Res Synth Methods. 2016;7:80\u201393.","journal-title":"Res Synth Methods"},{"key":"3238_CR31","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29:932\u201344.","journal-title":"Stat Med"},{"key":"3238_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.910656","volume":"13","author":"M Zhao","year":"2022","unstructured":"Zhao M, Shao T, Ren Y, Zhou C, Tang W. Identifying optimal PD-1\/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis. Front Pharmacol. 2022;13: 910656.","journal-title":"Front Pharmacol"},{"key":"3238_CR33","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209\u201319.","journal-title":"N Engl J Med"},{"key":"3238_CR34","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926\u201336.","journal-title":"N Engl J Med"},{"key":"3238_CR35","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1634\/theoncologist.2017-0072","volume":"22","author":"S Loibl","year":"2017","unstructured":"Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im S-A, et al. Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 Results. Oncologist. 2017;22:1028\u201338.","journal-title":"Oncologist"},{"key":"3238_CR36","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1158\/1078-0432.CCR-22-0305","volume":"28","author":"M Cristofanilli","year":"2022","unstructured":"Cristofanilli M, Rugo HS, Im S-A, Slamon DJ, Harbeck N, Bondarenko I, et al. Overall survival with palbociclib and fulvestrant in women with HR+\/HER2- ABC: updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study. Clin Cancer Res. 2022;28:3433\u201342.","journal-title":"Clin Cancer Res"},{"key":"3238_CR37","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925\u201336.","journal-title":"N Engl J Med"},{"key":"3238_CR38","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","volume":"174","author":"HS Rugo","year":"2019","unstructured":"Rugo HS, Finn RS, Di\u00e9ras V, Ettl J, Lipatov O, Joy AA, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174:719\u201329.","journal-title":"Breast Cancer Res Treat"},{"key":"3238_CR39","doi-asserted-by":"crossref","unstructured":"Finn RS, Rugo HS, Dieras VC, Harbeck N, Im S-A, Gelmon KA, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer (ER+\/HER2\u2212 ABC): analyses from PALOMA-2. J Clin Oncol. 2022;40 17_suppl:LBA1003\u2013LBA1003.","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1003"},{"key":"3238_CR40","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejca.2022.08.012","volume":"175","author":"B Xu","year":"2022","unstructured":"Xu B, Hu X, Li W, Sun T, Shen K, Wang S, et al. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer: Primary results from PALOMA-4. Eur J Cancer. 2022;175:236\u201345.","journal-title":"Eur J Cancer"},{"key":"3238_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25\u201335.","journal-title":"Lancet Oncol"},{"key":"3238_CR42","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10549-020-05755-7","volume":"183","author":"RS Finn","year":"2020","unstructured":"Finn RS, Boer K, Bondarenko I, Patel R, Pinter T, Schmidt M, et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+\/HER2\u2212 advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Res Treat. 2020;183:419\u201328.","journal-title":"Breast Cancer Res Treat"},{"key":"3238_CR43","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738\u201348.","journal-title":"N Engl J Med"},{"key":"3238_CR44","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29:1541\u20137.","journal-title":"Ann Oncol"},{"key":"3238_CR45","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386:942\u201350.","journal-title":"N Engl J Med"},{"key":"3238_CR46","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465\u201372.","journal-title":"J Clin Oncol"},{"key":"3238_CR47","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","volume":"32","author":"DJ Slamon","year":"2021","unstructured":"Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021;32:1015\u201324.","journal-title":"Ann Oncol"},{"key":"3238_CR48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge","year":"2020","unstructured":"Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor\u2013positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2014MONARCH 2. JAMA Oncol. 2020;6:116.","journal-title":"JAMA Oncol"},{"key":"3238_CR49","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1158\/1078-0432.CCR-20-4685","volume":"27","author":"P Neven","year":"2021","unstructured":"Neven P, Johnston SRD, Toi M, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: subgroup analysis of patients receiving abemaciclib plus fulvestrant as first-line and second-line therapy for HR+, HER2\u2212-advanced breast cancer. Clin Cancer Res. 2021;27:5801\u20139.","journal-title":"Clin Cancer Res"},{"key":"3238_CR50","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","volume":"5","author":"S Johnston","year":"2019","unstructured":"Johnston S, Martin M, Di Leo A, Im S-A, Awada A, Forrester T, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5\u20135.","journal-title":"NPJ Breast Cancer"},{"key":"3238_CR51","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638\u201346.","journal-title":"J Clin Oncol"},{"key":"3238_CR52","doi-asserted-by":"publisher","first-page":"S1384","DOI":"10.1016\/j.annonc.2022.08.009","volume":"33","author":"MP Goetz","year":"2022","unstructured":"Goetz MP, Toi M, Huober J, Sohn J, Tredan O, Park IH, et al. LBA15 MONARCH 3: interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). Ann Oncol. 2022;33:S1384.","journal-title":"Ann Oncol"},{"key":"3238_CR53","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1001\/jamaoncol.2021.4301","volume":"7","author":"A Llombart-Cussac","year":"2021","unstructured":"Llombart-Cussac A, P\u00e9rez-Garc\u00eda JM, Bellet M, Dalenc F, Gil-Gil M, Ru\u00edz-Borrego M, et al. Fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer. JAMA Oncol. 2021;7:1791.","journal-title":"JAMA Oncol"},{"key":"3238_CR54","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejca.2021.11.010","volume":"161","author":"J Albanell","year":"2022","unstructured":"Albanell J, Mart\u00ednez MT, Ramos M, O\u2019Connor M, de la Cruz-Merino L, Santaballa A, et al. Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive\/HER2\u2013advanced breast cancer: GEICAM\/2014\u201312 (FLIPPER). Eur J Cancer. 2022;161:26\u201337.","journal-title":"Eur J Cancer"},{"key":"3238_CR55","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz394.014","volume":"30","author":"Z Jiang","year":"2019","unstructured":"Jiang Z, Hu X, Zhang Q, Sun T, Yin Y, Li H, et al. LBA25 - MONARCHplus: a phase III trial of abemaciclib plus nonsteroidal aromatase inhibitor (NSAI) or fulvestrant (F) for women with HR+\/HER2- advanced breast cancer (ABC). Ann Oncol. 2019;30: v863.","journal-title":"Ann Oncol"},{"key":"3238_CR56","doi-asserted-by":"publisher","first-page":"175883592096392","DOI":"10.1177\/1758835920963925","volume":"12","author":"QY Zhang","year":"2020","unstructured":"Zhang QY, Sun T, Yin YM, Li HP, Yan M, Tong ZS, et al. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+\/HER2\u2013 advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol. 2020;12:175883592096392.","journal-title":"Ther Adv Med Oncol"},{"key":"3238_CR57","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","volume":"27","author":"B Xu","year":"2021","unstructured":"Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med. 2021;27:1904\u20139.","journal-title":"Nat Med"},{"key":"3238_CR58","doi-asserted-by":"publisher","first-page":"S642","DOI":"10.1016\/j.annonc.2022.07.268","volume":"33","author":"P Zhang","year":"2022","unstructured":"Zhang P, Zhang QY, Hu X, Li W, Tong Z, Sun T, et al. 229P Dalpiciclib plus fulvestrant in HR+\/HER2\u2212 advanced breast cancer (ABC): updated analysis from the phase III DAWNA-1 trial. Ann Oncol. 2022;33:S642\u20133.","journal-title":"Ann Oncol"},{"key":"3238_CR59","doi-asserted-by":"publisher","first-page":"S1384","DOI":"10.1016\/j.annonc.2022.08.010","volume":"33","author":"B Xu","year":"2022","unstructured":"Xu B, Zhang QY, Zhang P, Tong Z, Sun T, Li W, et al. LBA16 Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+\/HER2- advanced breast cancer (DAWNA-2): A phase III trial. Ann Oncol. 2022;33:S1384\u20135.","journal-title":"Ann Oncol"},{"key":"3238_CR60","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","volume":"30","author":"DA Yardley","year":"2013","unstructured":"Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, et al. Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30:870\u201384.","journal-title":"Adv Ther"},{"key":"3238_CR61","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","volume":"25","author":"M Piccart","year":"2014","unstructured":"Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014;25:2357\u201362.","journal-title":"Ann Oncol"},{"key":"3238_CR62","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1001\/jamaoncol.2019.2526","volume":"5","author":"P Schmid","year":"2019","unstructured":"Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, et al. Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor\u2013positive metastatic breast cancer. JAMA Oncol. 2019;5:1556.","journal-title":"JAMA Oncol"},{"key":"3238_CR63","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1200\/JCO.2017.76.9331","volume":"36","author":"N Kornblum","year":"2018","unstructured":"Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, et al. Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. J Clin Oncol. 2018;36:1556\u201363.","journal-title":"J Clin Oncol"},{"key":"3238_CR64","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1001\/jamaoncol.2018.2262","volume":"4","author":"G Jerusalem","year":"2018","unstructured":"Jerusalem G, de Boer RH, Hurvitz S, Yardley DA, Kovalenko E, Ejlertsen B, et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor\u2013positive, her2-negative advanced breast cancer. JAMA Oncol. 2018;4:1367.","journal-title":"JAMA Oncol"},{"key":"3238_CR65","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1056\/NEJMoa1201622","volume":"367","author":"RS Mehta","year":"2012","unstructured":"Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012;367:435\u201344.","journal-title":"N Engl J Med"},{"key":"3238_CR66","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1056\/NEJMoa1811714","volume":"380","author":"RS Mehta","year":"2019","unstructured":"Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, et al. Overall survival with fulvestrant plus anastrozole in metastatic breast cancer. N Engl J Med. 2019;380:1226\u201334.","journal-title":"N Engl J Med"},{"key":"3238_CR67","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","volume":"388","author":"JFR Robertson","year":"2016","unstructured":"Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. The Lancet. 2016;388:2997\u20133005.","journal-title":"The Lancet"},{"key":"3238_CR68","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(17)30688-5","volume":"19","author":"A Di Leo","year":"2018","unstructured":"Di Leo A, Johnston S, Lee KS, Ciruelos E, L\u00f8nning PE, Janni W, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:87\u2013100.","journal-title":"Lancet Oncol"},{"key":"3238_CR69","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andre","year":"2019","unstructured":"Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380:1929\u201340.","journal-title":"N Engl J Med"},{"key":"3238_CR70","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","volume":"32","author":"F Andr\u00e9","year":"2021","unstructured":"Andr\u00e9 F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2\u2013negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32:208\u201317.","journal-title":"Ann Oncol"},{"key":"3238_CR71","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1470-2045(22)00284-4","volume":"23","author":"SJ Howell","year":"2022","unstructured":"Howell SJ, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol. 2022;23:851\u201364.","journal-title":"Lancet Oncol"},{"key":"3238_CR72","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S1470-2045(19)30164-0","volume":"20","author":"Z Jiang","year":"2019","unstructured":"Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:806\u201315.","journal-title":"Lancet Oncol"},{"key":"3238_CR73","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ejca.2018.08.002","volume":"103","author":"M Campone","year":"2018","unstructured":"Campone M, Im S-A, Iwata H, Clemons M, Ito Y, Awada A, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. Eur J Cancer. 2018;103:147\u201354.","journal-title":"Eur J Cancer"},{"key":"3238_CR74","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(17)30376-5","volume":"18","author":"J Baselga","year":"2017","unstructured":"Baselga J, Im S-A, Iwata H, Cort\u00e9s J, De Laurentiis M, Jiang Z, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:904\u201316.","journal-title":"Lancet Oncol"},{"key":"3238_CR75","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1470-2045(16)00106-6","volume":"17","author":"IE Krop","year":"2016","unstructured":"Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17:811\u201321.","journal-title":"Lancet Oncol"},{"key":"3238_CR76","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1200\/JCO.2014.57.2388","volume":"33","author":"M Mart\u00edn","year":"2015","unstructured":"Mart\u00edn M, Loibl S, von Minckwitz G, Morales S, Martinez N, Guerrero A, et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole\/fulvestrant and avastin (LEA) study. J Clin Oncol. 2015;33:1045\u201352.","journal-title":"J Clin Oncol"},{"key":"3238_CR77","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1158\/1078-0432.CCR-21-2652","volume":"28","author":"J\u00c1 Garc\u00eda-S\u00e1enz","year":"2022","unstructured":"Garc\u00eda-S\u00e1enz J\u00c1, Mart\u00ednez-J\u00e1\u00f1ez N, Cubedo R, Jerez Y, Lahuerta A, Gonz\u00e1lez-Santiago S, et al. Sapanisertib plus fulvestrant in postmenopausal women with estrogen receptor\u2013positive\/HER2-negative advanced breast cancer after progression on aromatase inhibitor. Clin Cancer Res. 2022;28:1107\u201316.","journal-title":"Clin Cancer Res"},{"key":"3238_CR78","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.annonc.2020.10.596","volume":"32","author":"S Dent","year":"2021","unstructured":"Dent S, Cort\u00e9s J, Im YH, Di\u00e9ras V, Harbeck N, Krop IE, et al. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Ann Oncol. 2021;32:197\u2013207.","journal-title":"Ann Oncol"},{"key":"3238_CR79","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40:3246\u201356.","journal-title":"J Clin Oncol"},{"key":"3238_CR80","doi-asserted-by":"crossref","unstructured":"Connolly RM, Zhao F, Miller KD, Lee MJ, Piekarz RL, Smith KL, et al. E2112: Randomized phase III trial of endocrine therapy plus entinostat or placebo in hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN Cancer Research Group. J Clin Oncol. 2021;39:3171\u201381.","DOI":"10.1200\/JCO.21.00944"},{"key":"3238_CR81","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1200\/JCO.2012.43.7251","volume":"31","author":"DA Yardley","year":"2013","unstructured":"Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, et al. Randomized Phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013;31:2128\u201335.","journal-title":"J Clin Oncol"},{"key":"3238_CR82","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10549-016-3979-5","volume":"160","author":"S Johnston","year":"2016","unstructured":"Johnston S, Basik M, Hegg R, Lausoontornsiri W, Grzeda L, Clemons M, et al. Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: phase II randomized study in women with endocrine-therapy-na\u00efve advanced breast cancer. Breast Cancer Res Treat. 2016;160:91\u20139.","journal-title":"Breast Cancer Res Treat"},{"key":"3238_CR83","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10549-013-2573-3","volume":"139","author":"H Iwata","year":"2013","unstructured":"Iwata H, Masuda N, Ohno S, Rai Y, Sato Y, Ohsumi S, et al. A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer. Breast Cancer Res Treat. 2013;139:441\u201351.","journal-title":"Breast Cancer Res Treat"},{"key":"3238_CR84","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1200\/JCO.2015.66.1595","volume":"34","author":"MN Dickler","year":"2016","unstructured":"Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, et al. Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor\u2013positive advanced-stage breast cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016;34:2602\u20139.","journal-title":"J Clin Oncol"},{"key":"3238_CR85","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","volume":"26","author":"S Chia","year":"2008","unstructured":"Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor\u2013positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26:1664\u201370.","journal-title":"J Clin Oncol"},{"key":"3238_CR86","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1200\/JCO.2014.56.7941","volume":"32","author":"HJ Burstein","year":"2014","unstructured":"Burstein HJ, Cirrincione CT, Barry WT, Chew HK, Tolaney SM, Lake DE, et al. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor\u2013positive advanced breast cancer\u2014CALGB 40302 (Alliance). J Clin Oncol. 2014;32:3959\u201366.","journal-title":"J Clin Oncol"},{"key":"3238_CR87","doi-asserted-by":"publisher","first-page":"16037","DOI":"10.1038\/npjbcancer.2016.37","volume":"2","author":"K Adelson","year":"2016","unstructured":"Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, et al. Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial. NPJ Breast Cancer. 2016;2:16037.","journal-title":"NPJ Breast Cancer"},{"key":"3238_CR88","doi-asserted-by":"crossref","unstructured":"Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Trivedi MS, Novik Y, et al. A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4\/6 inhibition (CDK 4\/6i) in patients (pts) with unresectable or hormone receptor\u2013positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. J Clin Oncol. 2022;40 17_suppl:LBA1004\u2013LBA1004.","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1004"},{"key":"3238_CR89","doi-asserted-by":"crossref","unstructured":"Mayer EL, Wander SA, Regan MM, DeMichele AM, Forero A, Rimawi MF, et al. Abstract OT3\u201305\u201311: Palbociclib after CDK inhibitor and endocrine therapy (PACE): A randomized phase II study of fulvestrant versus palbociclib plus fulvestrant, with and without avelumab, for CDK inhibitor pre-treated HR+\/HER2- metastatic breast cancer. Cancer Res. 2018;78 4_Supplement:OT3\u201305\u201311-OT3\u201305\u201311.","DOI":"10.1158\/1538-7445.SABCS17-OT3-05-11"},{"key":"3238_CR90","doi-asserted-by":"crossref","unstructured":"Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, et al. Abstract GS3\u201306: GS3\u201306 Palbociclib After CDK4\/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+\/HER2- Metastatic Breast Cancer. Cancer Res. 2023;83 5_Supplement:GS3\u201306-GS3\u201306.","DOI":"10.1158\/1538-7445.SABCS22-GS3-06"},{"key":"3238_CR91","doi-asserted-by":"crossref","unstructured":"Oliveira M, Pominchuck D, Nowecki Z, Hamilton E, Kulyaba Y, Andabekov T, et al. Abstract GS3\u201302: GS3\u201302 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. Cancer Res. 2023;83 5_Supplement:GS3\u201302-GS3\u201302.","DOI":"10.1158\/1538-7445.SABCS22-GS3-02"},{"key":"3238_CR92","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2020.12.013","volume":"32","author":"M Martin","year":"2021","unstructured":"Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Turner N, Ciruelos EM, et al. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial\u2014PEARL. Ann Oncol. 2021;32:488\u201399.","journal-title":"Ann Oncol"},{"key":"3238_CR93","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2022.03.006","volume":"168","author":"M Mart\u00edn","year":"2022","unstructured":"Mart\u00edn M, Zielinski C, Ruiz-Borrego M, Carrasco E, Ciruelos EM, Mu\u00f1oz M, et al. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. Eur J Cancer. 2022;168:12\u201324.","journal-title":"Eur J Cancer"},{"key":"3238_CR94","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3390\/biom13091422","volume":"13","author":"IM Stanciu","year":"2023","unstructured":"Stanciu IM, Parosanu AI, Nitipir C. An overview of the safety profile and clinical impact of CDK4\/6 inhibitors in breast cancer-A systematic review of randomized phase II and III clinical trials. Biomolecules. 2023;13:1422.","journal-title":"Biomolecules"},{"key":"3238_CR95","doi-asserted-by":"crossref","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. NCCN Guidelines\u00ae Insights: Breast Cancer, Version 4.2023. J Natl Compr Cancer Netw JNCCN. 2023;21:594\u2013608.","DOI":"10.6004\/jnccn.2023.0031"},{"key":"3238_CR96","unstructured":"FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-elacestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer. Accessed 16 Dec 2023."},{"key":"3238_CR97","unstructured":"EMA Recommends Granting a Marketing Authorisation for Elacestrant. https:\/\/www.esmo.org\/oncology-news\/ema-recommends-granting-a-marketing-authorisation-for-elacestrant. Accessed 16 Dec 2023."},{"key":"3238_CR98","unstructured":"FDA approves capivasertib with fulvestrant for breast cancer. 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-capivasertib-fulvestrant-breast-cancer. Accessed 16 Dec 2023."},{"key":"3238_CR99","unstructured":"ESMO Living Guidelines | ESMO. https:\/\/www.esmo.org\/living-guidelines\/esmo-metastatic-breast-cancer-living-guideline. Accessed 16 Dec 2023."},{"key":"3238_CR100","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019618","volume":"99","author":"CH Lee","year":"2020","unstructured":"Lee CH, Kang YN, Ho CL, Lin C, Chen PH, Wu YY, et al. Endocrine therapies in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, pretreated, advanced breast cancer: A network meta-analysis. Med Baltim. 2020;99: e19618.","journal-title":"Med Baltim"},{"key":"3238_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100332","volume":"6","author":"E Munzone","year":"2021","unstructured":"Munzone E, Pagan E, Bagnardi V, Montagna E, Cancello G, Dellapasqua S, et al. Systematic review and meta-analysis of post-progression outcomes in ER+\/HER2- metastatic breast cancer after CDK4\/6 inhibitors within randomized clinical trials. ESMO Open. 2021;6: 100332.","journal-title":"ESMO Open"},{"key":"3238_CR102","doi-asserted-by":"crossref","unstructured":"Brandao M, Maurer C, Ziegelmann PK, Ponde NF, Ferreira A, Martel S. Endocrine therapy-based treatments in hormone receptor-positive\/HER2-negative advanced breast cancer: systematic review and network meta-analysis. ESMO Open. 2020;5:e000842.","DOI":"10.1136\/esmoopen-2020-000842"},{"key":"3238_CR103","first-page":"7252","volume":"25","author":"Q Tian","year":"2021","unstructured":"Tian Q, Gao H, Zhou Y, Yang J. Overall survival and progression-free survival with cyclin-dependent kinase 4\/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials. Eur Rev Med Pharmacol Sci. 2021;25:7252\u201367.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3238_CR104","unstructured":"FDA approves sacituzumab govitecan-hziy for HR-positive breast cancer. 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-sacituzumab-govitecan-hziy-hr-positive-breast-cancer. Accessed 16 Dec 2023."},{"key":"3238_CR105","doi-asserted-by":"publisher","first-page":"6447","DOI":"10.3390\/curroncol30070474","volume":"30","author":"T Xiao","year":"2023","unstructured":"Xiao T, Ali S, Mata D, Lohmann AE, Blanchette PS. Antibody-Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond-A 2023 Review. Curr Oncol. 2023;30:6447\u201361.","journal-title":"Curr Oncol"},{"key":"3238_CR106","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41523-023-00578-3","volume":"9","author":"J Ma","year":"2023","unstructured":"Ma J, Chan JJ, Toh CH, Yap YS. Emerging systemic therapy options beyond CDK4\/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer. NPJ Breast Cancer. 2023;9:74.","journal-title":"NPJ Breast Cancer"},{"key":"3238_CR107","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1136\/bmjebm-2022-111928","volume":"28","author":"B Sadeghirad","year":"2023","unstructured":"Sadeghirad B, Foroutan F, Zoratti MJ, Busse JW, Brignardello-Petersen R, Guyatt G, et al. Theory and practice of Bayesian and frequentist frameworks for network meta-analysis. BMJ Evid Based Med. 2023;28:204\u20139.","journal-title":"BMJ Evid Based Med"},{"key":"3238_CR108","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1186\/s12885-018-4978-1","volume":"18","author":"A van Ommen-Nijhof","year":"2018","unstructured":"van Ommen-Nijhof A, Konings IR, van Zeijl C, Uyl-de GC, van der Noort V, Jager A, et al. Selecting the optimal position of CDK4\/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial. BMC Cancer. 2018;18:1146.","journal-title":"BMC Cancer"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-03238-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-023-03238-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-03238-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T22:48:56Z","timestamp":1731019736000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-023-03238-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":108,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3238"],"URL":"https:\/\/doi.org\/10.1186\/s12916-023-03238-2","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,12]]},"assertion":[{"value":"18 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed to the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}